Navigating ethics in the large grey zone of unproven stem cell treatments

To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue.

Go to the profile of Regenerative Medicine
Dec 05, 2017
0
0
Upvote 0 Comment

EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine.

You can now read the lay summary for the article entitled, “Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation” from Sarah Chan [1].

Ethical and safety concerns are being raised about the increasing number of clinics marketing unproven stem cell therapies around the world. Addressing these issues requires understanding both the scope of what unproven treatments are and how clinics offering these therapies fit into the broader picture of regenerative medicine translation at the interface of research, health care, commercial markets and government policy.  

What questions & challenges are raised? What insight and direction does this give for research policies? To find out, read the full lay summary on the EuroStemCell website here: https://www.eurostemcell.org/regenerative-medicine-society/navigating-ethics-large-grey-zone-unproven-stem-cell-treatments

The full original article can be accessed here: https://www.futuremedicine.com/doi/10.2217/rme-2017-0065

 

References

[1] Chan S. Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation. Regen. Med. 12(7), 839–851 (2017).

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (www.future-science-group.com/journalprofile/regenerative-medicine/), where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.